OasisLMS

Genetic Therapies Bootcamp | Medical Genetics in Ophthalmology | Joint Keynote

Date of Release: March 23, 2026

Expiration Date: March 31, 2028
P.A.C.E.® Expiration Date: March 31, 2027

Credits offered: AMA PRA Category 1 Credits™, ASCLS P.A.C.E.®, NSGC (Pending)

Estimate time of completion: 7.5 hours

Maximize your learning — and your savings. When you purchase our two featured courses together as a bundle, you’ll receive 7.5 hours of accredited CME credit and enjoy a reduced package price.

Instead of enrolling in each course separately, bundle them today to:

• Save on registration fees
• Gain comprehensive insights across both courses

Course 1: Genetic Therapies Bootcamp: Foundations, Frontiers, and Clinical Engagement

Description

Explore the transformative world of gene therapy at your own pace with this comprehensive on-demand course, designed for clinical geneticists, laboratory geneticists, and genetic counselors. Gain an insightful overview of both FDA-approved and emerging gene therapies across a variety of conditions.

Learn from leading experts about the principles of clinical trials, discover the toolkit of cutting-edge therapeutic strategies, and understand the collaborative relationships shaping the field. Delve into discussions on ethical considerations and acquire practical knowledge to enhance patient care and advance your professional growth in the rapidly evolving landscape of gene therapy.

Target Audience

Clinical and Laboratory geneticists, trainees, genetic counselors.

Learning Objectives

At the conclusion of this session, participants should be able to:

• Evaluate the current state of gene therapy for rare disorder, including successes, challenges, future directions, citing recent case studies.
• Explain the principles of clinical trial design as applicable to rare disorders, including phases, regulatory considerations, n=1 studies and good clinical practice.
• Describe the different therapeutic strategies in gene therapy for monogenic disorders, including gene replacement, antisense oligonucleotides (ASO), and gene editing.
• Apply knowledge of gene therapy therapeutic strategies and clinical trials to inform their own clinical practice, research endeavors and career pathway opportunities.
• Explore the potential future role of medical geneticists in the therapeutic era, including in clinical trials and in the long-term management of patients treated with gene therapy.
• Recognize ethical considerations in genetic therapies, including consent, access and long-term impacts.
• Compare limitations, risks and benefits of different genetic therapy approaches.
• Analyze interdisciplinary collaborations among academia, industry and healthcare teams
• Apply case studies to illustrate the diversity of approaches and outcomes in genetic therapy applications
• Recognize opportunities for future ongoing education in genetic therapies for professional development.

Agenda

Course 2: Medical Genetics in Ophthalmology: Through the Lens of Genetics-Informed Therapies

Description

Ophthalmic genetics is a well-established field for management, diagnosis, and counseling of rare genetic eye disorders and genetic systemic disorders with eye manifestations in children and adults. Multiple clinical models and training pathways are available for medical geneticists, ophthalmologists and genetic counselors interested in this career specialty. This workshop aims to provide a description of the clinical landscape of ophthalmic genetics, unique diagnostic and therapeutic challenges, including highlighting the growing field of gene-targeted and gene-agnostic therapies. Participants will gain insight into training, clinical phenotyping, including advanced multimodal imaging, genetic testing, and gene therapy considerations, as well as the opportunity to interact with leaders in ophthalmic genetics clinical and translational research. We will provide an open forum for clinical geneticists and ophthalmologists to present cases which remain unsolved or represent an example of the power of ocular genetics.

Target Audience

ACMG members, medical geneticists, laboratory geneticists, genetic counselors, ophthalmologists with experience in genetics practice, and ophthalmologists with interest in genetics training.

Learning Objectives

At the conclusion of this session, participants should be able to:

• Define key ophthalmic terms used in genetic diagnosis.
• Distinguish between common congenital ocular anomalies and their genetic implications.
• Recognize how precise terminology improves communication between medical geneticists and ophthalmologists.
• Describe current training pathways integrating genetics and ophthalmology.
• Compare educational approaches for ophthalmologists, medical geneticists, and genetic counselors.
• Identify strategies to develop genetics-focused training within ophthalmology programs.
• Explain the essential components of a multidisciplinary ophthalmic genetics clinic.
• Differentiate between genetic testing modalities used in ocular disease diagnosis.
• Evaluate approaches for selecting appropriate clinical, research, or sponsored testing.
• Summarize current and emerging gene therapy options for ocular genetic disease.
• Discuss gene-directed and gene-agnostic therapeutic approaches.
• Examine the patient experience and ethical considerations surrounding ocular gene therapy.

Agenda

Joint Closing Address: The Evolution of Gene Therapy — Milestones, Challenges, and Future Directions:

Presenter: Eric Pierce, MD, PhD
This on-demand joint closing session is the recorded presentation from the live event and serves as the last session where attendees from both the Gene Therapy Bootcamp and the Ophthalmology Symposium come together. The session explores the evolution of gene therapy, highlighting key milestones, ongoing challenges, and future directions in the field.

Course 1: Genetic Therapies Bootcamp: Foundations, Frontiers, and Clinical Engagement

	Maya Chopra, MBBS, FRACP Assistant Professor, Boston Children's Hospital
	Joan Stoler, MD, FACMG Associate Professor, Boston Children’s Hospital /Harvard Medical School

	Austin Larson, MD Associate Professor, University of Colorado
	Elizabeth Berry-Kravis, MD, PhD Professor of Pediatrics and Neurological Sciences, Rush University Medical Center
	PJ Brooks  Acting Director of NCATS’ Division of Rare Diseases Research Innovation
	Rebecca Ahrens-Nicklas, MD, PhD, FACMG Assistant Professor, The Children’s Hospital of Philadelphia
	Timothy Yu, MD, PhD Neurologist, Havard Medical School
	Toni Pearson, MD Neurologist, Nationwide Children’s Hospital

Course 2: Medical Genetics in Ophthalmology: Through the Lens of Genetics-Informed Therapies

	Alex Levin, MD, MS University of Rochester Medical Center
	Tomas Aleman, MD University of Pennsylvania- Perelman School of Medicine
	Gavin Arno Greenwood Genetic Center
	Brian Brooks, MD, PhD Ophthalmic Genetics & Visual Function, National Eye Institute
	Peter Campochiaro, MD Johns Hopkins Hospital School of Medicine
	Amy Laster, BS, PhD The Foundation Fighting Blindness
	Kristy Lee, MS University of North Carolina at Chapel Hill
	Lev Prasov, MD Departments of Ophthalmology and Visual Sciences and Human Genetics, NIH
	Eric Pierce, MD, PhD Harvard Medical School
	Anne Slavotinek, MBBS, PhD, FACMG Cincinnati Children's Hospital Medical Center
	Elias Traboulsi, MD, MEd Cleveland Clinic Cole Eye Institute
	David Valle, MD, FACMG Johns Hopkins University School of Medicine
	Celeste Wyman, ScM, CGC Flaum Eye Institute (URMC)

Accredited Continuing Education Information:

CME AMA PRA Category 1 Credits^TM, ASCLS P.A.C.E.®, NSGC (Pending)

Accreditation

The American College of Medical Genetics and Genomics is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The American College of Medical Genetics and Genomics designates this enduring activity for a maximum of 7.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The American Medical Association (AMA) defines physicians as those individuals who have obtained an MD, DO, or equivalent medical degree from another country. Non-physicians may request a certificate of attendance for their participation.

ASCLS P.A.C.E.® CEU's 

ACMG is approved as a provider of continuing education programs in the clinical laboratory sciences by the American Society for Clinical Laboratory Science (ASCLS) Professional Acknowledgment for Continuing Education (P.A.C.E.®) Program.

ACMG is approved by the Florida Board of Clinical Laboratory Personnel as CE Provider (50-11878). This course is registered with CEBroker #20-1332029. ACMG is approved by the California Department of Health Services through the ASCLS P.A.C.E.® (275-100-26). This activity has been approved for 7.5 P.A.C.E.® CEU's.

National Society of Genetic Counselors (NSGC):

This event has been submitted to the National Society of Genetic Counselors (NSGC) for approval of Category 1 CEUs. The American Board of Genetic Counseling (ABGC) accepts CEUs approved by NSGC for purposes of recertification. Approval for the requested CEUs and contact hours is currently pending.

Claiming your Educational Credits

This activity consists of: View content, take a post-test, the test may be taken as often as necessary to achieve a passing score of 80% or better is required to receive credit.  If you do not achieve a passing score, the program will identify which questions you answered incorrectly so that you can review the module and try again. Complete the evaluation form.

Learner Data Consent

ACMG Education reports learner data to respective agency boards and you will be asked for consent during the evaluation process. Your compliance with deadlines and completing evaluations are part of the process in meeting learner needs and ACMG’s education mission.

Technical Support:
You can reach us by email at education@acmg.net or call 301-718-9603.
Support Center Hours: Monday – Friday, 9:00 AM – 5:00 PM Eastern Time.